CCR2 and metabolic dysfunction-associated steatohepatitis: A randomized, placebo-controlled, multicenter phase 2b clinical trial will evaluate the safety and tolerability of Tropifexor (TXR, a non-BA agonist of FXR) and Cenicriviroc (a CCR2/5 antagonist, CVC) combination therapy in patients with NASH and liver fibrosis (NCT03517540).